Chase-ing biotech? By Eric Pierce
& Shaun Brown
Staff Writers

It may not have been lost on biotech companies that the business media last week focused on disappointment over the small size of Chase Manhattan's $1.35 billion acquisition deal for Hambrecht & Quist, or on the big commercial bank's long-anticipated entree into high tech equity banking. What everyone in biotech knows - that H&Q has been a mainstay of biotech banking in this decade - was virtually ignored.